source
- Amgen reports positive Phase 3 results for Sjögren's drug; Novartis announces $900M radioligand partnershipAmgen said its CD40 ligand antagonist dazodalibep met the primary endpoint in a Phase 3 trial for Sjögren's syndrome, marking a notable achievement for the company. Novartis disclosed a $900 milli…
- Amgen's Dazodalibep Shows Positive Results in First Phase 3 Trial for Sjögren’s SyndromeAmgen announced that its experimental drug dazodalibep, acquired through the Horizon Therapeutics acquisition, met the primary endpoint in the first of two Phase 3 trials for Sjögren’s syndrome, a…